1. Home
  2. /
  3. Science & IP
Documented by design

Evidence you can
interrogate.

Our proprietary strains are isolated, characterized, and documented to support demanding veterinary and regulatory conversations.

Three flagship programsPatent-pending platformPartner files under NDA
Conceptual biological fieldEditorial visualization — not study data
Enter the strain files
02 / 06CT-01 · Gastrointestinal

Gastrointestinal
resilience.

A multi-strain Lactobacillus and Bifidobacterium consortium selected for high gastric-acid survival and rapid intestinal colonization in dogs and cats.

Acid survival
92%at pH 2.0 over four hours
Bile tolerance
> 0.5%validated colonization potential
At manufacture
1010 CFU/g24-month validated stability
Safety screen
Clearno acquired resistance genes detected
A laboratory technician operating a pipette during a generic laboratory procedure
Method contextLicensed editorial photography; not a Costinia laboratory
03 / 06CT-02 · Dental

Oral microbiome
balance.

A targeted Lactobacillus reuteri-derived strain engineered for oral-cavity colonization. Shown to reduce volatile sulfur compounds and support periodontal health.

Format stability
Saliva-stableviable in lyophilized oral chews
Persistence
6 hoursdocumented tongue adhesion post-administration
Applications
3 formatskibble, chews, water additives
Pilot observation
38%VSC reduction observed in pilot data
A shelf of laboratory glassware in a generic laboratory setting
Laboratory contextLicensed editorial photography; not a Costinia laboratory
04 / 06CT-03 · Skin & coat

Dermal and coat
support.

A Bifidobacterium-led consortium developed to support the gut–skin axis in dogs and cats with atopic or sensitive-skin presentations.

Profile
BalancedTH1/TH2 response in cytokine screening
Temperature
40°Cheat-stable for warm-climate distribution
Topical use
2 formatsdocumented for shampoo and mousse
Veterinary pilot
Under NDApartner preview; publication pending
A researcher handling prepared laboratory samples during a generic research workflow
Research workflow contextDaniel Sone / NCI via Unsplash; not Costinia personnel
05 / 06Intellectual property

A defensible
scientific moat.

Our proprietary strains are the subject of pending applications covering composition, manufacturing process, and application methods. We state that status clearly because long-term partners deserve precision.

Patent statusApplications pending
Request the 32-page technical whitepaper

Partner documentation / 06 files

  1. 01
    Genomic data sheets

    Full 16S rRNA sequences and whole-genome sequencing summaries.

  2. 02
    Stability reports

    Real-time and accelerated shelf-life data with CFU retention curves.

  3. 03
    Safety profiles

    Antimicrobial resistance, virulence factor, and toxigenicity screening aligned with EFSA QPS criteria.

  4. 04
    In-vitro studies

    Acid and bile tolerance, adhesion, antimicrobial activity, and competitive exclusion data.

  5. 05
    In-vivo pilots

    Select pilot clinical data available to qualified partners under NDA.

  6. 06
    Regulatory dossiers

    Traceability for EU, UK, and selected international submissions.

06 / 06Technical conversation

Bring us the
difficult questions.

Discuss a strain, application, dossier, or evidence requirement directly with our science team.

Email the science team Explore private label